Literature DB >> 27790634

Dataset reporting detection of breast cancer-related HER2I655V polymorphism using allele-specific polymerase chain reaction.

Bugi Ratno Budiarto1.   

Abstract

The dataset presented in this article is related to the research article entitled "Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study" (B.R. Budiarto, Desriani, 2016) [1] with some modification in primers used and in PCR optimization strategy to eliminate false-positive result that may occur in HER2I655V polymorphism detection. Combining a new set of primers with PCR gradient, The allele-specific PCR well performs to detect all type of breast cancer-originated HER2I655V genotypes. The validation of this method was done using Sanger DNA sequencing, offering an alternative tool for HER2I655V polymorphism detection in another type of cancer.

Entities:  

Keywords:  Allele-specific PCR; Breast cancer; HER2; Ile655Val; Single nucleotide polymorphism

Year:  2016        PMID: 27790634      PMCID: PMC5072141          DOI: 10.1016/j.dib.2016.09.033

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data The data provide a straightforward strategy for clarifying the possibility of a false-positive amplification generated by allele-specific PCR. The data provide the technique to determine the proper dosage of DNA template used in allele-specific PCR for the success of HER2genotyping. Data comparison of HER2 polymorphism between our improved allele-specific PCR with Sanger DNA sequencing is provided in a way to validate the method easily. Allele frequency data for breast cancer –related HER2 polymorphism can be used as a reference for researchers who conduct similar experiments for HER2 polymorphism studies with breast cancer risk related to specific demography or other races.

Data

The detection of breast cancer-related HER2 polymorphism using allele-specific PCR using mismatch-specific primers strategy as shown in Fig. 1. The optimum annealing temperature for breast cancer-related HER2 genotyping in allele-specific PCR was done using gradient PCR strategy with SNP-known DNA template (Fig. 2). To test sensitivity of the method, we used two types of genomic DNA which contain AA genotype or AG genotype in HER2 gene as allele representative with diluted ranging from 0.019 up to 10 ng of the template at optimized PCR condition (Fig. 3). Then, the reliability of allele-specific PCR was compared with data of Sanger DNA sequencing by looking the consistency of HER2 genotypes data between two methods (Fig. 4 and Table 1). The allele frequency of breast cancer-originated HER2 obtained from allele-specific PCR was similar with an allele frequency data of breast cancer-originated HER2 from Asian population (Table 2).
Fig. 1

Illustration of allele-specific PCR and its primers design and position towards target HER2 polymorphism. Nucleotides with red color at 3′ end of primer indicate the mismatched base pairing that correspond to SNP site. Nucleotides with green color at 3rd position indicate the mismatched base pairing to increase SNP discrimination level. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).

Fig. 2

Determination of the best annealing temperature for allele-specific PCR in typing HER2 polymorphism. Lane 1, 3, 5 and 7 are PCR products of AG genotype (142 bp and 168 bp), lane 2 and 6 are PCR products of AA genotype (142 bp), and lane 4 and 8 are NTC (Non-Template Control). No.6 genomic DNA was used as DNA template for AG genotype, while DEV genomic DNA was used as DNA template for AA genotype. M is 100 bp DNA ladder. The PCR product was run on 3% agarose under UV illumination.

Fig. 3

Sensitivity test of allele-specific PCR in genotyping HER2 polymorphism. PCR was performed using optimized PCR condition where annealing temperature was at 54.3 °C. NTC was Non-Template Control. The PCR product was run on 3% agarose under UV illumination.

Fig. 4

Allele-specific PCR of HER2 polymorphism for 10 of 61 samples of breast cancer patients. (A) Gel electrophoresis data of allele-specific PCR: Yellow arrow head indicated AA genotype with band size of 142 bp; green arrow head indicated GG genotype with band size of 168 bp; red arrows head indicated AA/GG genotype represented two different of PCR band products. The PCR product was run on 3% agarose under UV illumination. M is 100 bp DNA ladder meanwhile NTC (Non-template control) was pointed in lane 11. (B) Sanger DNA sequencing chromatograms of HER2 polymorphism. Yellow arrow head indicated AA genotype; green arrow head indicated GG genotype; red arrows head indicated AA/GG genotype. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).

Table 1

Distribution data of HER2 polymorphism in two methods comparison.

Allelic typesMethods
Sanger sequencingAllele-specific PCR
AA37 (60.6%)37 (60.6%)
GG2 (3.3%)2 (3.3%)
AG22 (36.1%)22(36.1%)
Failed0 (0%)0 (0%)
Total samples61 (100%)61 (100%)

Percentage means the number of samples produces correct genotype in total samples tested

Table 2

Genotype frequency of HER2 polymorphism showed by our data versus published data.

AuthorYear of publicationGenotypes (%)
Sample populationP value
AA
GG
AG
IleVal
Our experiment60.63.336.1Asian
Allele frequency0.790.21
Xie et al. [5]200071.73.225.1Asian>0.05a
An et al. [6]200578.52.818.6Asian
Naidu et al. [7]200871.73.424.7Asian
Allele frequency0.850.15
Keshava et al. [8]200164.94.330.8European>0.05b
Millikan et al. [9]200359.66.334.02European
Nelson et al. [10]200558.25.636.2European
Allele frequency0.780.22
Millikan et al. [9]200387.51.111.7African<0.05c
Siddig et al. [11]200882.41.516.2African
kallel et al. [12]200987.82.79.5African
Allele frequency0.920.08

Note: Each of P value represented the different of genotype frequency of HER2 obtained from Chi-Square test.

no siginificant event was observed between genotype frequency of HER2 in our experiment with Asian population.

no siginificant event was observed between genotype frequency of HER2 in our experiment with European population.

a siginificant event was observed between genotype frequency of HER2 in our experiment with African population.

Experimental design, materials and methods

Sample collection and genomic DNA extraction

Sixty-one breast cancer tissues from archived biopsies as the frozen section were collected from M. Djamil Hospital Padang, West Sumatera Province. Genomic DNA was then extracted followed manual tissue DNA extraction protocol (Pure Link Genomic DNA Mini Kit; Invitrogen). We have also prepared two types of genomic DNA with SNPs have previously been determined using a Sanger DNA sequencing method. No.6 tissue-retrieved genomic DNA with HER2 gene carries AG genotype while DEV (abbreviaton of patient׳s name) tissue-retrieved genomic DNA with HER2 gene carries AA genotype. All subjects enrolled in this experiment were approved by the local ethics committee, issued by the Ministry of Health, Republic of Indonesia.

Allele-specific PCR optimization

The optimum annealing temperature for allele-specific PCR was determined using genomic DNA with known SNPs. Each of 12.5 µL reaction mixture was contained 11.25 µL of PCR Super Mix (Invitrogen), 0.1 µM of allele-specific forward primer (5′-CCAGCCCTCTGACGTCCAGCA-3′), 0.06 µM of long allele-specific forward primer (5′-GCGGGCAGGGCGGCGGGGGCGGGGCCCCAGCCCTCTGACGTCCACCG-3′), 0.15 µM of reverse primer (5′-TCCGTTTCCTGCAGCAGTCTCC-3′), and 0.25 µl (~3–6 ng) of DNA template. The Primers ratio used in this experiment followed the optimized PCR method as suggested by Germer and Higuchi, [2] and Gaundet et al. [3] with minor modification. The PCR amplification profile was as follows: initial denaturation at 95 °C for 5 min, followed by 35 cycles of denaturation at 95 °C for 20 s, gradient temperature annealing from 54.3 °C, 54.9 °C, 57.3 °C, 59.7 °C, 60.8 °C to 62.3 °C for 20 s, and extension at 72 °C for 30 s (Kyratec Super Cycler Thermal Cycler, Australia). All PCR tubes, distilled water, pipette tips, and pipettes were pre-treated by exposing them on UV-light for ±15-20 minute prior to use. All PCR reagent mixing was done under laminar air flow.

Sensitivity test of allele-specific PCR

Two genomic DNA with known SNPs (No.6 genomic DNA for AG genotype and DEV genomic DNA for AA genotype) were fixed at 50 ng/µL to make serial dilution ranging from 10 ng declining to 0.019 ng. These diluted DNA then were applied as a template for allele-specific PCR reaction at optimum annealing temperature with PCR reagents and PCR amplification profile followed method mentioned above.

Validating and genotyping test using allele-specific PCR

Sixty-one samples of breast cancer were tested for HER2 polymorphism using optimized allele-specific PCR. The PCR condition and temperature profile were the same as mentioned above except for annealing temperature was fixed at 54.3 °C. The method was validated by direct Sanger DNA sequencing of 61 sample of breast cancer patients by firstly amplified DNA fragment using primer pairs HER2_F (5′-CCAGCCCTCTGACGTCCAT-3′) and HER2_R (5′-TCCGTTTCCTGCAGCAGTCTCC-3′) generating 142 bp PCR product. The PCR amplification profile was as follows: initial denaturation at 95 °C for 5 min, followed by 35 cycles of denaturation at 95 °C for 30 s, an nealing temperature at 60 °C for 30 s, and extension at 72 °C for 30 s. This PCR product was sequenced using HER2_R primer only done by First-Base Asia Ltd.

Comparing allele frequency of HER obtained from our data to published data

Data were tested for statistical significance by using Statistical Package for the Social Sciences software system SPSS-17 statistical software (SPSS, Chicago,IL). Frequency of each HER2 allele was calculated using formulation frequency of Ile=f(Ile/Ile)+0.5f(IleVal), whereas frequency of Val=f(Val/Val)+0.5f (IleVal). Chi-square test was used to analyze differences in genotype frequencies between our data with published dataset to evaluate any possible deviation from Hardy–Weinberg equilibrium of our genotyping data. Genotype frequencies are interpreted as statistically significant different if only the P value is less than 0.05 [4].
Subject areaBiology
More specific subject areaMolecular Biology, Cancer research
Type of dataTable and figure
How data was acquiredPCR, DNA sequencing and statistics analysis
Data formatRaw, analyzed
Experimental factorsDNA was extracted form frozen section of breast cancer tissue
Experimental featuresAllele-Specific PCR using two spesific primer (Forward direction) and one common primer (revere direction) to detect HER2I655Vpolymorphism
Data source locationResearch Center for Biotechnology, Indonesian Institute of Science (LIPI), Indonesia
Data accessibilityData is available with this article
  11 in total

1.  Allele-specific PCR in SNP genotyping.

Authors:  Muriel Gaudet; Anna-Giulia Fara; Isacco Beritognolo; Maurizio Sabatti
Journal:  Methods Mol Biol       Date:  2009

2.  Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States.

Authors:  C Keshava; E C McCanlies; N Keshava; M S Wolff; A Weston
Journal:  Cancer Lett       Date:  2001-11-08       Impact factor: 8.679

3.  Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

Authors:  D Xie; X O Shu; Z Deng; W Q Wen; K E Creek; Q Dai; Y T Gao; F Jin; W Zheng
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

4.  Her2 genotype and breast cancer progression in Korean women.

Authors:  Hee Jung An; Nam Keun Kim; Doyeun Oh; Sae Hyun Kim; Min Jung Park; Moon Young Jung; Haeyoun Kang; Seung Gi Kim; Kyung Po Lee; Kyung Sik Lee
Journal:  Pathol Int       Date:  2005-02       Impact factor: 2.534

5.  HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

Authors:  Robert Millikan; Allison Eaton; Kendra Worley; Lorna Biscocho; Elizabeth Hodgson; Wen-Yi Huang; Joseph Geradts; Mary Iacocca; David Cowan; Kathleen Conway; Lynn Dressler
Journal:  Breast Cancer Res Treat       Date:  2003-06       Impact factor: 4.872

6.  HER2 polymorphisms and breast cancer in Tunisian women.

Authors:  Imen Kallel; Najla Kharrat; Suad Al-fadhly; Maha Rebai; Abdelmajid Khabir; Tahia Sallemi Boudawara; Ahmed Rebaï
Journal:  Genet Test Mol Biomarkers       Date:  2010-02

7.  Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.

Authors:  R Naidu; C H Yip; N A Taib
Journal:  Neoplasma       Date:  2008       Impact factor: 2.575

8.  HER-2/neu Ile655Val polymorphism and the risk of breast cancer.

Authors:  Awatif Siddig; Abdelrahim Osman Mohamed; Hammed Kamal; Salma Awad; Ahmed H Hassan; Erika Zilahi; Mohammed Al-Haj; Roos Bernsen; Abdu Adem
Journal:  Ann N Y Acad Sci       Date:  2008-09       Impact factor: 5.691

9.  A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.

Authors:  Stephanie E Nelson; Michael N Gould; John M Hampton; Amy Trentham-Dietz
Journal:  Breast Cancer Res       Date:  2005-03-11       Impact factor: 6.466

10.  Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study.

Authors:  Bugi Ratno Budiarto
Journal:  Sci Pharm       Date:  2016-02-14
View more
  1 in total

Review 1.  Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.

Authors:  Sara Elena Rebuzzi; Lodovica Zullo; Giovanni Rossi; Massimiliano Grassi; Veronica Murianni; Marco Tagliamento; Arsela Prelaj; Simona Coco; Luca Longo; Maria Giovanna Dal Bello; Angela Alama; Chiara Dellepiane; Elisa Bennicelli; Umberto Malapelle; Carlo Genova
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.